Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus gemcitabine versus sequential paclitaxel then gemcitabine for first-line recurrent metastatic breast cancer
ChiCTR-IPR-14005583Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paclitaxel and gemcitabine in breast cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-free survival, Objective response rate and 1 more. Started Oct 2014; status: recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-IPR-14005583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005583.